It has been shown that CLL and DLBCL patients acquire resistance to ibrutinib through mutations in BTK and its substrate phospholipase C gamma 2 (PLCG2)6,17, MYD8818, and CARD1117 following prolonged treatment. Here, PLCG2 is linked to diffuse large B-cell lymphoma.